JD Health: Net profit to grow by 29.1% to 5.375 billion yuan by 2025, with over 100 new drug launches throughout the year

Recently, JD Health released its annual performance report for the fiscal year ending December 31, 2025. The company’s revenue reached 73.441 billion yuan, a year-on-year increase of 26.3%; gross profit was 18.199 billion yuan, up 36.7% year-on-year; net profit attributable to shareholders was 5.375 billion yuan, an increase of 29.1%.

In the management discussion, it was mentioned that in 2025, the company will continue to leverage its supply chain advantages, deepen cooperation with pharmaceutical companies, and launch more than 100 new drugs throughout the year, a significant increase compared to over 30 in 2024. Additionally, policy support for the health consumption sector has promoted the application of AI in healthcare, enhancing user experience. The company also continues to strengthen integrated online and offline healthcare services, with JD Daojia’s rapid testing business maintaining strong growth momentum, with order volume increasing by 81.9% year-on-year.

In health management, the company’s AI health concierge service has received positive feedback. As of December 31, 2025, AI doctor “Dawei” has completed hundreds of millions of interactions, with a positive feedback rate of 98%. In terms of business segments, the company’s retail pharmacies and online healthcare services continue to expand. By the end of 2025, the company’s self-operated pharmacy stores exceeded 300.

(JD Health Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Healthcare